Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092976 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
A Phase 4 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00092976 is a Phase 4 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT00092976, a Phase 4 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.
Interventions
- DRUG ReFacto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00092976
The ClinicalTrials.gov registry entry for NCT00092976 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ReFacto is the first listed.
NCT00092976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00092976 about?
NCT00092976 is a clinical study titled "Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery". The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.
What is the current status of trial NCT00092976?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2003-02. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00092976?
The interventions under investigation include: ReFacto (DRUG).
Who is sponsoring clinical trial NCT00092976?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.